On March 29, 2018, the online magazine Il Bo published an update on the ADIPOA-2 clinical trial ongoing at the University of Padua and other sites. Read the story here.
This author has yet to write their bio.Meanwhile lets just say that we are proud aoife contributed a whooping 22 entries.
Entries by aoife
‘Mesenchymal stem cells derived exosomes and microparticles protect cartilage and bone from degradation in osteoarthritis’ by authors: Stella Cosenza, Maxime Ruiz, Karine Toupet, Christian Jorgensen & Danièle Noël was published online on 24 November 2017 in the open access Nature publication Scientific Reports. Abstract: Mesenchymal stem or stromal cells (MSCs) exert chondroprotective effects in preclinical models of osteoarthritis (OA). Most […]
ADIPOA-2 researchers at NUI Galway exhibited at the Galway Science and Technology Forum on 26 November 2017. In excess of 20,000 people attended the exhibition day. The NUI Galway regenerative medicine stand was the brainchild of Dr Siobhán Gaughan who works across several EU-funded stem cell projects coordinated at NUI Galway. Researchers Georgina Shaw, Amy Burke […]
Does it help your fitness to have an event as a goal when you are training? Can cartoons and comics help children to achieve better results in tests? How would you even find out? Dr Siobhán Gaughan, NUI Galway Programmme Manager of ADIPOA-2, VISICORT and AUTOSTEM was on hand at the awards ceremony for a […]
Hosted by Leiden University Medical Center, the EU MSC2 2017 meeting in Leiden, NL on September 12th and 13th will assemble twelve EU-funded, mesenchymal stromal cell-focussed consortia. Projects to be presented include: REDDSTAR, REACH, Nephstrom, SCIENCE, VISICORT and Adipoa-2, AUTOSTEM, BOOSTB4, SEPCELL, RESSTORE, RETHRIM, Stellar, MERLIN, and RESPINE. This two day, interactive meeting will be held at the Stadsgehoorzaal Leiden. Three overarching aspects of the EU-MSC2 meeting include: mechanisms […]
ADIPOA2 partners Evangelisches Waldkrankenhaus Spandau today announced the enrollment of the first patients in the German arm of the ADIPOA2 trial.
The ADIPOA2 has successfully secured regulatory approval for the Italian part of its clinical trial. Click here and here to see some of the coverage of this exciting news in the Italian media.
ADIPOA2’s Italian partners, Instituto Ortopedico Rizzoli de Bologna, announce the launch of the Italian arm of the ADIPOA2 trial. Click here for a copy of IOR’s press release.
ADIPOA2 researchers Prof. Frank Barry and Dr Mary Murphy (NUIG) attended the 13th World Congress of the International Cartilage Repair Society in Sorrento, Italy, on 24th – 27th September. The work of the ADIPOA2 project was highlighted during the conference sessions.
ADIPOA2 was one of a number of projects discussed at the A FACTT meeting in Galway this week. A FACTT is an Action to Focus and Accelerate Cell-based Tolerance-Inducing Therapies, funded through the COST (European Cooperation in Science and Technology) Programme. The meeting is being hosted by NUIG and runs from 5-7 October.
- ADIPOA-2 clinical study highlighted in University of Padua publicationApril 9, 2018 - 9:46 am
- New ADIPOA2 research published from Centre Hospitalier Universitaire MontpellierNovember 29, 2017 - 2:38 pm
- ADIPOA2 meets the public at the Galway Science & Technology Festival 2017November 27, 2017 - 10:44 am
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643809. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.